Utama › Limfoma Folikular › Massachusetts › Boston
Kajian klinikal Limfoma Folikular di Boston, MA
17 kajian untuk Limfoma Folikular sedang mencari peserta di lokasi dalam dan sekitar Boston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Mengambil pesertaFasa 3
- Tufts Medical Center, Boston
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
Mengambil pesertaFasa 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Mengambil pesertaFasa 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
Mengambil pesertaFasa 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Mengambil pesertaFasa 3
- Beth Israel Deaconess Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Mengambil pesertaFasa 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Mengambil pesertaFasa 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Mengambil pesertaFasa 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
Odronextamab in Low Tumor Volume Advanced FL
Mengambil pesertaFasa 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Mengambil pesertaFasa 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Mengambil pesertaFasa 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Mengambil pesertaFasa 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Kajian Limfoma Folikular di bandar lain
- New York City, NY24 kajian
- Milwaukee, WI19 kajian
- Nashville, TN18 kajian
- Houston, TX18 kajian
- Baldwin Park, CA16 kajian
- Seattle, WA15 kajian
- Durham, NC15 kajian
- Columbus, OH13 kajian
- Salt Lake City, UT13 kajian
- San Antonio, TX12 kajian
- Chicago, IL12 kajian
- Philadelphia, PA12 kajian
Kajian lain di Boston
- Kanser Payudara111 kajian
- Kanser Paru-paru Bukan Sel Kecil90 kajian
- Kanser (semua jenis)86 kajian
- Kanser Kolorektal63 kajian
- Kanser Metastatik63 kajian
- Kanser Paru-paru62 kajian
- Kanser Ovari61 kajian
- Kanser Prostat59 kajian
- Depresi52 kajian
- Kanser Endometrium50 kajian
- Kegagalan Jantung44 kajian
- Leukemia Mieloid Akut44 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.